Amgen secures FDA Priority Review for tarlatamab to treat SCLC
Tarlatamab is an investigational, delta-like ligand 3 (DLL3) targeting Bispecific T-cell Engager (BiTE) therapy intended for the treatment…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
14 Dec 23
Tarlatamab is an investigational, delta-like ligand 3 (DLL3) targeting Bispecific T-cell Engager (BiTE) therapy intended for the treatment…
12 Dec 23
The authorisation of the indication also converts previous conditional approval for Jemperli to full approval as a monotherapy…
07 Dec 23
The approval was based on the APPLY-PNH trial in adults with PNH and anaemia despite prior anti-C5 treatment…
07 Dec 23
The approval was based on the interim analysis of 386 patients in the Phase 3 KarMMa-3 study in…
28 Nov 23
The FDA approval is based on positive data from the Phase 3 DeFi trial, in which Ogsiveo significantly…
27 Nov 23
The NMPA has also granted Priority Review designation to GFH925 for treating patients with advanced non-small cell lung…
24 Nov 23
Designed to provide protection for infants throughout an entire RSV season, AK0610 has been genetically engineered from a…
23 Nov 23
The next-generation ROS1 tyrosine kinase inhibitor (TKI) is intended for use in adult patients dealing with locally advanced…
20 Nov 23
AstraZeneca secured the FDA approval based on positive results from Phase 3 CAPItello-291 clinical trial that evaluated the…
17 Nov 23
Casgevy is a genetically modified autologous CD34+ cell-enriched population that contains human hematopoietic stem and progenitor cells, edited…